MUC1 and non-small cell lung carcinoma: In a phase 3 clinical trial of patients with non-small cell lung cancer (NSCLC), tecemotide, another vaccine against MUC1, combined with chemoradiotherapy showed no significant difference in OS compared to a placebo (NCT00409188) 22.